Is there such a thing as a good death? What might that mean to you? Dying pain-free, without distress or suffering? Dying ...

The FDA has approved TNKase, a tissue plasminogen, clot-dissolving agent, to treat acute ischemic stroke in adults, according ...

The discovery by Rutgers Health researchers suggests a potential new approach to improving fitness in older adults.

Researchers conducted a retrospective cohort study to assess the association between intraoperative nerve monitoring and postoperative outcomes in thyroidectomy.

The Food and Drug Administration (FDA) has granted Priority Review to the Biologics License Application (BLA) for deramiocel (CAP-1002) for the treatment ...

The unidentified ailment has sickened 1,300 people and led to more than 50 deaths. Regardless of the cause, experts say ...

Patients with rheumatoid arthritis who use biological DMARDs are unlikely to achieve sustained DMARD-free remission.

The FDA has approved TNKase, a new, fast-acting stroke treatment that dissolves blood clots more efficiently, marking a significant advancement in stroke therapy and clot-busting technology.

Researchers sought to determine whether zanubrutinib is more beneficial than ibrutinib in patients with CLL/SLL.

Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) has approved TNKase® (tenecteplase), a thrombolytic or clot-dissolving agent, for the treatment ...

The approval was supported by data from the registry-linked, parallel group, open-label, randomized AcT trial, which compared tenecteplase to alteplase.